Overview

Trans Arterial Radio Embolization (TARE)

Transarterial radioembolization (TARE), also known as selective internal radiotherapy (SIRT), represents a form of internal radiation therapy designed to address liver cancer or liver metastases arising from other cancers such as colon cancer. This treatment option becomes relevant when individuals are no longer eligible for surgical intervention, ablation methods (RFA/MWA), and/or synthetic chemotherapy. Its primary aim is to provide relief from symptoms associated with liver tumors rather than aiming for a cure for the underlying cause. Radioembolization has the potential to prolong life expectancy and enhance overall quality of life. In certain cases, patients may become eligible for a liver transplant following this procedure.

Looking for a TARE Specialist in Jaipur? Contact us!

Searching for an expert who can give you proper consultation and treatment for Trans Arterial Radio Embolization? Then here we are. Contact us immediately!

Meet Our Doctor

Dr. Nikhil Bansal

MD, PGDHHM, FVIR, FIPM

TARE Specialist in Jaipur

Dr. Nikhil Bansal stands as the foremost Interventional Radiologist in Jaipur recognized for his expertise and commitment to delivering exceptional medical care. Specializing in Trans Arterial Radio Embolization (TARE), Dr. Bansal brings unparalleled skill and knowledge to the field of interventional radiology. His dedication to patient well-being and cutting-edge practices has positioned him as a trusted medical professional in Jaipur. 

With a focus on TARE, a vital procedure in the realm of internal radiation therapy, Dr. Bansal ensures that individuals receive top-notch care for conditions such as liver cancer and liver metastases. His commitment to excellence has earned him a reputation as the go-to Interventional Radiologist for those seeking specialized and effective medical interventions in Jaipur.

15

years of
experience


What is TARE?

Trans Arterial Radio Embolization (TARE) is an advanced and minimally invasive interventional radiology procedure employed in the treatment of liver cancer and liver metastases. This innovative technique involves the targeted delivery of radioactive microspheres directly into the blood vessels that supply the tumor. By doing so, TARE restricts the blood flow to the cancerous cells, delivering a concentrated dose of radiation precisely to the affected area. This approach not only minimizes damage to surrounding healthy tissues but also enhances the effectiveness of the treatment.

TARE is particularly valuable for patients who may not be suitable candidates for surgery or other conventional treatments. As a result, it offers a promising alternative for individuals facing liver malignancies, contributing to improved outcomes and enhanced quality of life. This sophisticated procedure is often spearheaded by skilled Interventional Radiologists, leveraging their expertise to bring about targeted and impactful interventions in the realm of oncological care.

What to expect?

The treatment process comprises two phases: a pretreatment phase and the actual treatment phase.

In the initial stage, a pre-SIRT procedure, an exploratory/pretreatment step, will be conducted. Before this, a comprehensive examination will be conducted. Blood vessels not leading to the liver will be blocked. Using a local anesthetic, an interventional radiologist will administer a test dose of a radioactive tracer into the hepatic artery through a thin tube (catheter) inserted via the femoral vein. Subsequently, a scan at the nuclear health department will determine if the protein is exclusively absorbed in the liver.

Once this scan is complete, eligibility for treatment and the appropriate dosage can be determined. The interventional radiologist will provide further details, and in many cases, patients can return home by the end of the procedure day.

Moving on to the second phase, the SIRT treatment occurs approximately a week or two after the pretreatment. This phase follows a similar course as the pretreatment. The interventional radiologist administers radioactive beads through the hepatic vein toward the tumor.

These beads become lodged in the blood vessels surrounding and within the tumor, emitting radiation to destroy the tumor cells and shrink the tumor. Yttrium-90 (Y-90) or Holmium-166 (Ho-166) radioactive isotopes are commonly used. Since the radiation targets only the tumor, a higher radiation dose can be employed compared to other treatment methods, enhancing effectiveness.

It's important to note potential side effects from the treatment. Following the procedure, an overnight stay at the hospital is required. After the PET-CT scan, the interventional radiologist will discuss the treatment results with the patient.

What is the condition treated by the TARE procedure?

Trans Arterial Radio Embolization (TARE) is primarily employed in the treatment of liver conditions, specifically targeting liver cancer and liver metastases. This procedure is particularly beneficial for individuals who may no longer be viable candidates for surgery or other conventional treatments.

TARE is commonly used to address primary liver tumors, such as hepatocellular carcinoma (HCC), and metastatic liver lesions resulting from other cancers, including colorectal cancer. The procedure involves the precise delivery of radioactive microspheres into the blood vessels that supply the tumor, thereby restricting blood flow and delivering a concentrated dose of radiation to the affected area.

This targeted approach minimizes damage to surrounding healthy tissues while maximizing the therapeutic impact on the cancerous cells. TARE represents a valuable option for patients facing specific liver malignancies, offering an alternative avenue for treatment and contributing to improved outcomes in the realm of interventional oncology.

What are the risks and complications?

The primary complication encountered is post-embolization syndrome, affecting approximately 20 to 70% of patients. Symptoms encom pass fatigue, mild fever, nausea, vomiting, and abdominal pain. While these symptoms typically peak in severity during the initial two weeks post-treatment, they may persist for up to a month.

Less frequently observed complications involve bruising, edema, hepatic impairment, and infection. In rare instances, individuals may exhibit an allergic reaction to the contrast agent. The iodine present in the contrast agent can, in extremely uncommon cases, lead to a kidney response.


Work Shedule

Get In Touch In The
Mean Time.

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s

  • Monday – Saturday 09:00 AM – 08:00 PM
  • Sunday  – Closed

Want to Visit Our Clinic? Please Get In Touchwith us

Make An Appointment

    FAQ

    What is TARE, and how does it differ from other liver cancer treatments?

    TARE, or Trans Arterial Radio Embolization, is a minimally invasive procedure designed for treating liver cancer and metastases. Unlike some other treatments, TARE delivers targeted radiation directly to the tumor site through microspheres, minimizing damage to surrounding healthy tissues.

    Who is a suitable candidate for TARE?

    TARE is often recommended for individuals who may not be eligible for surgery or traditional treatments. Candidates typically include those with liver cancer, particularly hepatocellular carcinoma (HCC), and metastatic liver lesions from other cancers, like colorectal cancer.

    What can patients expect during the TARE procedure?

    The TARE procedure involves the insertion of microspheres containing radioactive material into the blood vessels supplying the tumor. This process restricts blood flow to the cancerous cells, delivering a targeted dose of radiation. The procedure is minimally invasive, and many patients can return home on the same day.

    Are there potential side effects or risks associated with TARE?

    While TARE is generally well-tolerated, patients may experience post-embolization syndrome, including symptoms like fatigue, mild fever, nausea, and abdominal pain. Rare complications may include bruising, edema, hepatic impairment, infection, or allergic reactions to the contrast agent.

    What is the expected recovery time after undergoing TARE?

    Recovery times can vary, but many patients may need to stay in the hospital overnight for observation. Post-procedure, individuals will undergo follow-up appointments and assessments to monitor treatment effectiveness and address any potential side effects. Patients should consult with their healthcare team for personalized recovery guidance.